Inflammatory bowel diseas
Conditions
Interventions
Gold Standard:Gold Standard: endoscopic and histological examinations
Reference Standard: fecal calprotectin
Index test:Small molecule fluorescent probe (MPO-RFP-B)
Sponsors
Second Affiliated Hospital of Army Medical University, PLA
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for patients with ulcerative colitis and diarrhea-type irritable bowel syndrome: (1) Based on the diagnostic criteria in the "Chinese Guidelines for the Diagnosis and Treatment of Ulcerative Colitis (2023 · Xi'an)", combined with clinical, laboratory, imaging, endoscopic, and histopathological manifestations, a comprehensive analysis was conducted to confirm the diagnosis of inflammatory ulcerative colitis after excluding infectious and other non-infectious colitis; diagnosed as diarrhea-type irritable bowel syndrome according to the "Rome IV criteria". (2) Age 18-75 years old, gender not limited; (3) Patients need to collect feces during the treatment process for complete stool routine examination; (4) Patients can understand the research protocol and are willing to participate in this study, and provide written informed consent. Inclusion criteria for healthy volunteers: (1) Age 18-75 years old, gender not limited; (2) BMI between 18 - 28 kg/m²; (3) No systemic diseases and chronic diseases. (4) No surgical history in the past 1 year. (5) Healthy volunteers can understand the research protocol and are willing to participate in this study, agree to provide stool samples, and provide written informed consent.
Exclusion criteria
Exclusion criteria: Exclusion criteria for patients with ulcerative colitis and diarrhea-predominant irritable bowel syndrome: (1) Pregnant and lactating patients; (2) Patients with other inflammatory-related diseases; (3) Patients who have undergone progressive intestinal resection surgery, colostomy, or ileoanal pouch surgery within 3 months before enrollment; (4) Patients with clinically significant and severe, progressive or uncontrolled diseases or symptoms (including cardiovascular, neurological, mental, liver, gallbladder, kidney, blood, endocrine, etc.) in the past or currently; (5) Patients with malignant tumors; (6) Patients participating in other clinical studies. Exclusion criteria for healthy volunteers: (1) Pregnant and lactating patients; (2) Patients with a recent (<=4 weeks) history of drug use; (3) Patients who have received live vaccines within the past 1 month; (4) Patients participating in other clinical studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Myeloperoxidase;Fecal calprotectin; | — |
Countries
China
Contacts
Public ContactShiming Yang
Second Affiliated Hospital of Army Medical University, PLA
Outcome results
None listed